Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More GMP Warnings Likely As Botanicals Fail On Adulteration Awareness

This article was originally published in The Tan Sheet

Executive Summary

FDA supplement program official Daniel Fabricant says firms that fail to use appropriate tests for botanical ingredients are at risk of eliciting warning letters and other agency actions for violating GMPs. AHP’s Roy Upton says he sees FDA’s botanical expertise outpacing industry’s.


Related Content

FDA Will Crack Down On GMP Ingredient, Contaminant Spec Requirements
Senate Appropriators Call For Botanical Identity Testing Guidance
Ephedra Back On Regulatory Radar As Supplement Adulterant


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts